Loading...

BHVN BIOHAVEN LTD Product Launches 8-K Filing

BHVN

BHVN

BIOHAVEN LTD

(BHVN)

2024 8-K

Show Summary

Show Summary

Investor Meetings

Pre-Market Approval

Financial Statements

Equity Offerings

Financial Results

Investor Presentation

Q3 Financial Results

Positive Study Results

Share Resale Filing

Equity Offering

Financial Results Announcement

Financial Results Announcement

Annual Meeting Results

Presentation Update

Prospectus Supplement Filing

Financial Results Announcement

Investor Presentation

Equity Distribution Agreement

Earnings Reports

Regulation FD Disclosure

Earnings Reports

Amendment and Annual Meeting

Publication of Investor Pre...

Financial Results Announcement

Analyst and Investor Meetings

External Links:

Biohaven Ltd. announced positive topline results from a study showing that their drug, troriluzole, significantly slows disease progression in Spinocerebellar Ataxia (SCA), with a 50-70% slower decline compared to untreated patients over three years, and plans to submit a New Drug Application to the FDA by Q4 2024.

AI Assistant

BIOHAVEN LTD

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.